Global Access to Radiation Therapy for Cervical Cancer: The Cost of Inaction by Van Dyk, Jacob et al.
Western University
Scholarship@Western
Oncology Publications Oncology Department
10-1-2016
Global Access to Radiation Therapy for Cervical
Cancer: The Cost of Inaction
Jacob Van Dyk
The University of Western Ontario, vandyk@uwo.ca
D Rodin
Timothy Paul Hanna
E Burger
Eduardo Zubizarreta
See next page for additional authors
Follow this and additional works at: https://ir.lib.uwo.ca/oncpub
Part of the Medical Biophysics Commons, and the Oncology Commons
Citation of this paper:
Van Dyk, Jacob; Rodin, D; Hanna, Timothy Paul; Burger, E; Zubizarreta, Eduardo; Yap, Mei Ling; Barton, Michael; Atun, Rifat;
Knaul, Felicia Marie; Lievens, Y; Gospodarowicz, Mary K.; Jaffray, D A.; and Milosevic, M, "Global Access to Radiation Therapy for
Cervical Cancer: The Cost of Inaction" (2016). Oncology Publications. 116.
https://ir.lib.uwo.ca/oncpub/116
Authors
Jacob Van Dyk, D Rodin, Timothy Paul Hanna, E Burger, Eduardo Zubizarreta, Mei Ling Yap, Michael Barton,
Rifat Atun, Felicia Marie Knaul, Y Lievens, Mary K. Gospodarowicz, D A. Jaffray, and M Milosevic
This article is available at Scholarship@Western: https://ir.lib.uwo.ca/oncpub/116
physicians experienced in IMRT for the definitive treatment of cervical
cancer in preparation for a collaborative NRG clinical trial.
Materials/Methods: A consensus working group that had participated in
prior CTV definition was convened to contour on two treatment planning
CT scans. Observers were blinded to the corresponding MRI scans. One
case was an early cervical cancer and the other a loco-regionally advanced
case. Clinical vignettes for the two cases were distributed and each
participant was asked to draw CTV contours which included a CTV1
contour for the uterus/cervix and a CTV 2 contour for the vagina/para-
metria. Participants contoured on CT images of the pelvis using their own
treatment planning software. Nodal CTV contours have been well
described and were not included in this study. The CTV contours were then
analyzed for consistency and clarity of target delineation using an
expectation-maximization algorithm for simultaneous truth and perfor-
mance level estimation (STAPLE, CERR), with Kappa statistics as a
measure of agreement between observers.
Results: Contoured datasets were merged and analyzed for agreement.
CTV1 contours showed almost perfect agreement (Kappa > 0.8), while
CTV2 showed moderate agreement (0.4 < Kappa < 0.6) among observers
(see Table 1).
Conclusion: Agreement among the experienced gynecologic radiation
oncologists was excellent for CTV delineation in two representative
intact cervical cancer cases. Consensus demonstrated near perfect
agreement for the uterus and cervix and moderate agreement for the
vagina and parametria. The variability seen in vaginal contours was
primarily due to the vaginal length included in the CTV. The value of
this data, building on previously published guidelines for IMRT in the
post-operative setting and MRI guidance in the intact setting, provides
clinically valuable information to promote safety and quality among
radiation oncologists treating cervical carcinoma. Furthermore, this atlas
will be used for future trials utilizing IMRT for the definitive man-
agement of intact cervical cancer.
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Phase 1 Trial of Bone Marrow Sparing Intensity Modulated
Radiation Therapy With Concurrent Cisplatin and Gemcitabine in
Stage IB-IVA Cervical Cancer
L.K. Mell,1 C.C. Saenz,2 C.M. Yashar,1 M.T. McHale,2 J.P. Einck,1
M.E. Wright,2 S.S. Noticewala,1 R. Xu,2 S.C. Plaxe,2 and A.J. Mundt, III1;
1University of California, San Diego, La Jolla, CA, 2University of
California San Diego, La Jolla, CA
Purpose/Objective(s): To determine the maximum tolerated dose (MTD)
of gemcitabine (GEM) with concurrent weekly cisplatin (CIS) and bone
marrow-sparing (BMS) IMRT in women with Stage IB-IVA cervical
cancer.
Materials/Methods: Twenty-five women were enrolled in a phase I trial
with IMRT (45.0-50.4 Gy in 25-28 fractions), CIS (40 mg/m2 weekly) and
escalating doses of GEM (50-125 mg/m2 weekly) followed by HDR
brachytherapy (25-30 Gy in 4-5 fractions) as indicated. No adjuvant
chemotherapy was given. Cohorts 1 (50 mg/m2; nZ 6), 2 (75 mg/m2; nZ
5), 3 (100 mg/m2; n Z 3), and 4 (125 mg/m2; n Z 3) received CIS
immediately followed by GEM, while cohort 5 (125 mg/m2; n Z 5)
received GEM followed by CIS. Cohort 1E (nZ 3) received extended field
BMS-IMRT (EFRT) with concurrent CIS followed by 50 mg/m2 GEM
weekly. Primary IMRT sparing objectives were bone marrow (BM) (V10Gy
< 90%, V20Gy < 75%) and bowel (V45Gy<200 cc). Dose-limiting toxicity
(DLT) was defined as grade 4 neutropenia lasting >7 days, neutropenic
fever, grade 4 thrombocytopenia, symptomatic grade 3 thrombocytopenia,
grade 3 or 4 non-hematologic toxicity (HT), or any treatment related
morbidity causing a delay of therapy for > 2 weeks, consistent with a prior
GOG study (Rose et al., PMID: 17688925).
Results: Mean BM V10Gy, V20Gy, and mean dose were 82.6%, 63.4%, and
26.3 Gy, respectively. Mean bowel V45Gy and mean dose were 180.5 cc and
26.5 Gy, respectively. DLTs occurred in cohorts 1 and 2 due to protracted
nausea/vomiting, in cohort 5 due to grade 4 thrombocytopenia, and cohort
1E due to grade 3 infusion reaction. Acute grade  3 HT occurred in one
patient within cohort 1, four patients within cohort 2, two patients each in
cohorts 3 and 4, five patients in cohort 5, and three patients in cohort 1E.
Acute grade  3 gastrointestinal (GI) toxicity occurred in one patient in
cohort 1 and two patients each in cohorts 2 and 3. No patients treated with
125 mg/m2 developed grade 3 acute GI toxicity. Overall, 18 of 25 pa-
tients developed grade 3 toxicity and 3 of 25 patients developed grade 4
toxicity. Six patients developed late grade  2 toxicity: radiation proctitis
(n Z 4), vesicovaginal fistula (n Z 1), ureteral stricture (n Z 1), and
cystitis (n Z 1). Another patient had a small bowel obstruction attributed
to disease progression. With median follow-up of 16 months for patients
without para-aortic disease, 1-year (2-year) overall survival was 100%
(87.5%) and DFS was 93.3% (86.2%); one patient had LRF and two pa-
tients had distant metastasis.
Conclusion: With IMRT, concurrent CIS (40 mg/m2) and GEM
(125 mg/m2) are feasible with clinically manageable toxicity. MTD in this
study was not reached, and is higher than reported by Rose et al. Further
study is needed to determine the MTD of GEM with EFRT and whether
GEM/CIS sequencing affects toxicity.
Author Disclosure: L.K. Mell: None. C.C. Saenz: None. C.M. Yashar:
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Global Access to Radiation Therapy for Cervical Cancer: The Cost of
Inaction
D. Rodin,1 T.P. Hanna,2 E. Burger,3 E. Zubizarreta,4 M.L. Yap,5
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Abstract 28; Table 1
STRUCTURE
MEASURE
Case 1 Case 2
CTV1 CTV2 CTV1 CTV2
Vol. Mean/Min/Max
(SD in cc)
225.1/189.4/
259.3
(22.4)
166.4/96.4/
238.0
(49.4)
322.3/283.6/
348.2
(21.1)
197.5/71.2/
365.1
(75.3)
STAPLE/Intersection/
Union Vol. (cc)
225.3/152.2/
305.6
224.9/18.2/
416.0
332.0/226.2/
423.3
253.1/10.56/
596.5
Kappa 0.82 0.56 0.87 0.50
Conformity Index (Mean
Vol./Union Vol.)
0.74 0.40 0.76 0.33
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Centre, Toronto, ON, Canada, 13Techna Institute, University Health
Network, Toronto, ON, Canada, 14Princess Margaret Cancer Centre/
University of Toronto, Toronto, ON, Canada
Purpose/Objective(s): Radiation therapy (RT) is a highly effective and
curative treatment for patients with invasive cervical cancer, and is the
standard of care for locally advanced disease. Although RT can be suc-
cessfully delivered in developing countries, major gaps in access have
resulted in substantial preventable morbidity and mortality, where nearly
90% of cervical cancer deaths occur. These gaps are multifactorial, but
assumptions about excessive cost of RT in these regions preclude effective
implementation. Using methodology developed for the Global Task Force
on Radiotherapy for Cancer Control (GTFRCC), we examined the validity
of these assumptions for the treatment of cervical cancer with external
beam radiation (EBRT) and brachytherapy (BT) in upper middle-income
income (UMIC), lower middle-income (LMIC) and low-income countries
(LIC).
Materials/Methods: Based on the GTFRCC evidence-based estimation
approach, we assumed that 71% of cervical cancer patients would require
RT, with a mean of 21 EBRT and 3 HDR BT fractions per course, resulting
in a 20% overall survival benefit. We developed a decision-analytic Mar-
kov model to assess three RT capacity scenarios from 2015 to 2035: 1) no
increase in capacity; 2) linear scale-up from baseline coverage in 2015 to
universal accessibility by 2035; and 3) immediate full availability. Model
outcomes included total life years (LYs) and economic productivity (US
Dollar). Costs, based on the GTFRCC efficiency model, and benefits were
discounted by 3% annually over a lifetime horizon.
Results: If no action is taken to shift current RT capacity to universal
accessibility, we project a loss of up to 21.4 million (M) LYs and $271.3
billion (B) due to cervical cancer alone over the next 20 years. Based on a
realistic linear investment model, RT yields an additional 9.8M LYs (2.9M
in LIC, 4.7M in LMIC, and 2.2M in UMIC) over 20 years, a $53.2B net
increase in economic productivity ($2.6B in LIC, $16.4B in LMIC, and
$34.2B in UMIC), and a broader societal net gain of $137.5B ($10.3B in
LIC, $44.8B in LMIC, and $82.4B in UMIC). The additional investment
necessary for HDR brachytherapy, an essential component of curative
treatment, was only 5.5% greater than EBRT alone.
Conclusion: The failure to ensure global availability of EBRT and BT to
treat cervical cancer would result in enormous human and economic
consequences over the next two decades. This loss would occur before the
benefits of primary cancer prevention strategies, such as HPV vaccination,
are realized. The present study demonstrates that a realistic investment
strategy over the next 20 years may yield a net economic benefit of up to
$150B USD and potentially further benefits beyond that point in time.
These findings support the value of scaling-up of EBRT and BT to treat
cervical cancer and help to justify their inclusion in national cancer control
planning.
Author Disclosure: D. Rodin: None. T.P. Hanna: None. E. Burger: None.
E. Zubizarreta: None. M. Yap: None. M.B. Barton: None. R. Atun:
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Total Treatment Duration for Cervical Cancer: Is 55 Days Still the
Goal in the Era of Concurrent Chemotherapy?
J.C. Hong, J. Foote, G. Broadwater, J. Sosa, S. Gaillard, L. Havrilesky,
and J.P. Chino; Duke University Medical Center, Durham, NC
Purpose/Objective(s): Prior studies have demonstrated the importance of
treatment duration (TD) in the management of cervical cancer treated with
radiation therapy (RT) for both locoregional control and overall survival
(OS). Most of the data support a 55-day goal for completion of all RT;
however, this is largely based on treatments with RT alone. This study uses
a contemporary national cohort treated with concurrent chemoradiation to
determine the time point by which completion of RT is most critical.
Materials/Methods: The National Cancer Data Base (NCDB) was queried
for all women with non-metastatic invasive cervical cancer diagnosed from
2004 to 2013 who underwent chemoradiation with external beam RT and
brachytherapy. To calculate the optimal TD, we randomly divided the
cohort into training and validation cohorts with preservation of the overall
TD distribution. The training set included 5685 women, and the validation
set included 5683. Bootstrapping was performed to generate 1000 simu-
lated training sets for which the recursive partitioning analysis (RPA) al-
gorithm was used to determine the optimal cut point of TD in each set to
maximize separation in survival. We restricted RPA to generate only one
cut point based on TD. The mean of the bootstrapped cut points was taken
forward to validation. The Kaplan-Meier method was used to estimate 5-
year OS in the validation cohort by defining two groups based on the
determined cut point and compared using the log-rank test. To describe the
entire cohort, a multivariate Cox proportional hazards model was
generated.
Results: A total of 11,368 women were included in the study with a mean
TD of 57.6 days and median TD of 54 days. The mean of the bootstrapped
TD cut points generated by RPA was 65 days (standard deviation 7 days).
In the validation set, 5-year OS was 68% (95% CI 66-69%) for those with a
TD less than 65 days and 57% (95% CI 55%-61%) for those with a TD of
65 days or longer (P < 0.001). For the entire cohort on multivariate
analysis, younger patient age, more recent diagnosis, geographic region,
metro location, non-government insurance, lower Charlson/Deyo comor-
bidity, squamous cell carcinoma, earlier stage, negative lymph nodes, and
TD less than 65 days were significantly associated with longer OS. After
adjusting for these covariates, TD less than 65 days remained significantly
associated with longer OS (HR 0.80 [95% CI 0.74-0.87], P < 0.001). By
comparison, with adjustment, TD less than 55 days also was associated
with OS but had less separation (HR 0.90 [95% CI 0.83-0.97]).
Conclusion: Shorter time to completion of radiation therapy is associated
with longer survival in women with cervical cancer receiving chemo-
radiation and should be a goal in treatment. We found the maximally
differential cutoff to be 65 days, slightly longer than the recommended
time of 55 days.
Author Disclosure: J.C. Hong: None. J. Foote: None. G. Broadwater:
None. J. Sosa: Data monitoring committee; Medullary Thyroid Cancer
Registry. Research Grant; NovoNordisk, GlaxoSmithKline, Astra Zeneca,
Eli Lilly. S. Gaillard: Research Grant; PharmaMar, Tetralogic, BMS,
Pfizer, Gradalis. Consultant; Genentech. L. Havrilesky: Employee; Bio-
ventus. J.P. Chino: Partnership; Nanoscint, Inc.
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The Influence of Hospital Volume on Disease Outcomes of
Advanced Uterine Cervical Cancer Patients: A Nationwide Cohort
Study of Taiwan
J.H. Hong,1 S.M. Lin,2 H.Y. Ku,3 T.W. Liu,3 and T.C. Chang4;
1Department of Medical Imaging and Radiological Sciences, College of
Medicine, Taoyuan 333, Taiwan, 2Chang Gung Memorial Hospital,
Taoyuan 333, Taiwan, 3National Health Research Institutes, Miaoli,
Taiwan, 4Chang Gung Memorial Hospital, Taoyuan, Taiwan
Purpose/Objective(s): To investigate the correlation between hospital
volume and clinical outcomes in locally advanced cervical cancer patients
treated with curative chemoradiation therapy or radiation therapy alone.
Materials/Methods: In this population-based retrospective cohort study,
total 8,968 patients diagnosed of FIGO stage I to IV uterine cervical cancer
from January 2007 to December 2013 were recorded in the Taiwan Na-
tional Health Insurance Research Databases. This study examined the
women who were treatment-naı¨ve before and received curative radiation
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